Drug intelligence / Profile preview

DTI-301

Development stage: Preclinical
Lead developer: Dignify Therapeutics
Modality: Peptides, Small Molecules
Administration: Rectal

Overview

DTI-301 is a rectal suppository drug candidate developed by Dignify Therapeutics for the rapid induction of on-demand defecation. It acts locally in the colorectum to initiate rapid contraction and produce defecation within minutes of administration. The mechanism of action involves modulation of the TRPV1 (vanilloid) receptor, which is associated with triggering colorectal contractions. This local delivery allows for lower doses and reduced systemic exposure. The drug is being investigated primarily for constipation, neurogenic bowel, and urination disorders[1][2][3][5].

Targets

TRPV1 (Transient receptor potential cation channel subfamily V member 1)

Beyond the preview

Go deeper on DTI-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DTI-301.

Explore the full profile